These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 21439312)

  • 1. Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis.
    Larsen AK; Ouaret D; El Ouadrani K; Petitprez A
    Pharmacol Ther; 2011 Jul; 131(1):80-90. PubMed ID: 21439312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
    Tabernero J
    Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to epidermal growth factor receptor-targeted therapy.
    Morgillo F; Lee HY
    Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
    Tortora G; Ciardiello F; Gasparini G
    Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
    Hicklin DJ; Ellis LM
    J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
    Viloria-Petit A; Crombet T; Jothy S; Hicklin D; Bohlen P; Schlaeppi JM; Rak J; Kerbel RS
    Cancer Res; 2001 Jul; 61(13):5090-101. PubMed ID: 11431346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma.
    Thomas SM; Bhola NE; Zhang Q; Contrucci SC; Wentzel AL; Freilino ML; Gooding WE; Siegfried JM; Chan DC; Grandis JR
    Cancer Res; 2006 Dec; 66(24):11831-9. PubMed ID: 17178880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delta-like 4/Notch signaling and its therapeutic implications.
    Yan M; Plowman GD
    Clin Cancer Res; 2007 Dec; 13(24):7243-6. PubMed ID: 18094402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the EGFR signaling in tumor microenvironment.
    De Luca A; Carotenuto A; Rachiglio A; Gallo M; Maiello MR; Aldinucci D; Pinto A; Normanno N
    J Cell Physiol; 2008 Mar; 214(3):559-67. PubMed ID: 17894407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
    Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C
    Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
    Baselga J; Arteaga CL
    J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development.
    Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Uemura M; Fukui H
    Oncol Rep; 2005 May; 13(5):853-7. PubMed ID: 15809749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
    Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms for oncogenic activation of the epidermal growth factor receptor.
    Zandi R; Larsen AB; Andersen P; Stockhausen MT; Poulsen HS
    Cell Signal; 2007 Oct; 19(10):2013-23. PubMed ID: 17681753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted agents for the treatment of advanced renal cell carcinoma.
    Stadler WM
    Cancer; 2005 Dec; 104(11):2323-33. PubMed ID: 16240452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
    Pradeep CR; Sunila ES; Kuttan G
    Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.